Pamela N. Munster, MD

home / authors / pamela-n-munster-md

Articles

22 Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer

22 Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer

Sara A. Hurvitz, MD;Anne F. Schott, MD;Cynthia X. Ma, MD, PhD;Rita Nanda, MD;George Zahrah;Natasha Hunter, MD;Antoinette R. Tan;Melinda L. Telli, MD;Jesus Anampa Mesias;Rinath M. Jeselsohn;Pamela N. Munster, MD;Eric Zhi;Elizabeth Duperret;Cecile Mather;Erika P. Hamilton, MD;Hyo S Han
August 4th 2024
24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study

24 ARV-471, a PROTAC Estrogen Receptor (ER) Degrader in Advanced ER+/Human Epidermal Growth Factor Receptor 2 (HER2)– Breast Cancer: Phase 2 Expansion (VERITAC) of a Phase 1/2 Study

Sara A. Hurvitz, MD;Anne F. Schott, MD;Cynthia X. Ma, MD, PhD;Erika P. Hamilton, MD;Rita Nanda, MD;George Zahrah;Natasha Hunter, MD;Antoinette R. Tan;Melinda L. Telli, MD;Jesus Anampa Mesias;Rinath Jeselsohn;Pamela N. Munster, MD;Haolan Lu;Richard Gedrich;Cecile Mather;Janaki Parameswaran;Hyo S Han
April 27th 2023
Fertility Preservation and Breast Cancer: A Complex Problem

Fertility Preservation and Breast Cancer: A Complex Problem

Pamela N. Munster, MD
June 15th 2013

A considerable number of women with breast cancer are diagnosed during their reproductive years. In the short period of time in which newly diagnosed women will need to make decisions about surgical options and adjuvant therapy, younger women with breast cancer also face the potential impairment or complete loss of their fertility.

Site Logo

Update on the Management of Advanced Breast Cancer

Monica Fornier, MD;Pamela N. Munster, MD;Andrew D. Seidman, MD
May 1st 1999

Recent trials comparing single-agent vs combination therapy in metastatic breast cancer suggest that it may be time to reconsider the belief that combination chemotherapy is the gold standard of treatment. Based on the

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Photosensitive Facial Rash Depicted Along with Polyarticular Arthralgias
Published: April 30th 2011 | Updated: July 26th 2025
Photosensitive Facial Rash Depicted Along with Polyarticular Arthralgias